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Peripheral nerve regeneration is a slow process that can be associated with limited
outcomes and thus a search for novel and effective therapy for peripheral nerve injury
and disease is crucial. Here, we found that roscovitine, a synthetic purine nucleoside
analog, enhances neurite outgrowth in neuronal-like PC12 cells. Furthermore, ex vivo
analysis of pre-injured adult rat dorsal root ganglion (DRG) neurons showed that
roscovitine enhances neurite regrowth in these cells. Likewise, in vivo transected sciatic
nerves in rats locally perfused with roscovitine had augmented repopulation of new
myelinated axons beyond the transection zone. By mass spectrometry, we found that
roscovitine interacts with tubulin and actin. It interacts directly with tubulin and causes a
dose-dependent induction of tubulin polymerization as well as enhances Guanosine-5’-
triphosphate (GTP)-dependent tubulin polymerization. Conversely, roscovitine interacts
indirectly with actin and counteracts the inhibitory effect of cyclin-dependent kinases
5 (Cdk5) on Actin-Related Proteins 2/3 (Arp2/3)-dependent actin polymerization, and
thus, causes actin polymerization. Moreover, in the presence of neurotrophic factors
such as nerve growth factor (NGF), roscovitine-enhanced neurite outgrowth is mediated
by increased activation of the extracellular signal-regulated kinases 1/2 (ERK1/2) and
p38 mitogen-activated protein kinase (MAPK) pathways. Since microtubule and F-actin
dynamics are critical for axonal regrowth, the ability of roscovitine to activate the ERK1/2
and p38 MAPK pathways and support polymerization of tubulin and actin indicate a
major role for this purine nucleoside analog in the promotion of axonal regeneration.
Together, our findings demonstrate a therapeutic potential for the purine nucleoside
analog, roscovitine, in peripheral nerve injury.
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INTRODUCTION
Unlike in the central nervous system, some degree of axonal regeneration and functional recovery
is possible after injury in the peripheral nervous system. However, the process is slow and many
times incomplete. Following injury, Wallerian-like degeneration (WLD) occurs in the denervated
distal stump where myelin and myelin-associated glycoproteins are broken down to allow
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axonal regeneration (Stoll et al., 2002). This event correlates with
upregulation of cytosolic and secreted forms of phospholipase
A2 in Schwann cells (SC; De et al., 2003), which undergo
dedifferentiation to promote a change in the damaged nerve
environment to support neuron survival and axon regrowth
(Jessen and Mirsky, 2008).
Axonal regrowth is one of the cellular processes that
require modulation of actin and tubulin polymerization (Eng
et al., 1999; Richardson et al., 2009). Indeed, during injured
peripheral nerve recovery, the growth cone depends on
the upregulation of tubulin subunits in its core and in the
core of the trailing axon as well as actin, which forms the
filopodia. Thus, tubulin and actin form the major cytoskeletal
framework of elongating axons of the regenerating nerve
(Chierzi et al., 2005; Vogelaar et al., 2009).
A multitude of endogenous and exogenous factors have been
demonstrated to have an impact on the speed and direction
of growth of regenerating axons. For example, the naturally
occurring purine nucleoside, inosine, has been implicated in
collateral axon growth in the corticospinal tract after focal
traumatic brain injury and stroke (Dachir et al., 2014). In
addition, the purine nucleosides, adenosine and guanosine, have
been suggested to influence axonal degeneration after injury
of dorsal root ganglia neurons (Press and Milbrandt, 2009).
Furthermore, adenosine was found to aid axon preservation after
injury (Press and Milbrandt, 2009). These observations suggest
that purine nucleosides may have the ability to protect axon
integrity.
A synthetic purine analog, R-roscovitine (also known
as CYC202 and Seliciclib), interacts with a number of
proteins, including cyclin-dependent kinases (Cdks), camodulin-
dependent protein kinases (CaM kinases) and extracellular
signal-regulated kinases (ERK; Bach et al., 2005), and has a
varying inhibitory effect on these kinases (Meijer et al., 1997;
Planchais et al., 1997). Roscovitine is particularly known as
an inhibitor of Cdks, which are key regulators of cell cycle
progression. Interestingly, inhibiting the cell cycle has been
shown to cause decreased neuronal death as well as improved
sensory motor recovery following spinal cord injury (Wu et al.,
2011), and purine nucleosides have been demonstrated to
protect axon integrity (Press and Milbrandt, 2009) and support
axon growth (Dachir et al., 2014). However, there have also
been studies showing that roscovitine inhibits neurite outgrowth
(Harada et al., 2001; Lee and Kim, 2004; Carter et al., 2008).
Thus, the role of roscovitine in neurite outgrowth remains to be
elucidated.
Although roscovitine inhibits mitogen-activated protein
kinase (MAPKs), it is a poor inhibitor of these kinases with
IC50 values of 34 µM, 14 µM and >10 µM for ERK1, ERK2
and p38 MAPK, respectively, in in vitro purified enzyme assays
(Meijer et al., 1997). The molecular mechanism by which
roscovitine inhibits protein kinase activity involves competition
for adenosine 5′-triphosphate (ATP)-binding pockets within
the enzyme (De Azevedo et al., 1997; Gray et al., 1999). The
binding of roscovitine is a reversible process, and based on
pharmacokinetic studies using intravenous injections in mouse
and rat models, it shows a high degree of dissemination and
rapid metabolomic degradation (Vita et al., 2004; Nutley et al.,
2005; Raynaud et al., 2005). Interestingly, roscovitine is currently
being explored as a therapeutic agent for specific types of cancer
such as non-small cell lung cancer (Hamilton et al., 2014) and
nasopharyngeal cancer (Hui et al., 2009) as well as therapy for
Cushing’s disease (Liu et al., 2015).
Previously, roscovitine has been shown to rescue actin stress
fibers formation in Rat-2 fibroblast cells that overexpress CKIγ2.
It was thought that this was achieved through a Cdk-independent
p27KIP pathway (Latreille et al., 2012). Roscovitine has also
been correlated with microtubule formation in mitotic S2
Drosophila cells. It was believed that this correlation involved
inactivation of Cdk1 (Moutinho-Pereira et al., 2010). In yet
another study, roscovitine was associated with the formation of
cytoskeletal aggregates in apoptotic bodies in human CHP212
neuroblastoma cells (van Engeland et al., 1997). Based on
these findings, we came to the hypothesis that roscovitine may
interact with cytoskeletal components, particularly actin and
tubulin, and that it is possible that following peripheral nerve
injury, exposure to roscovitine could result in the alteration of
actin and tubulin dynamics and subsequently promote axonal
regeneration.
Previous investigations on the signaling cascades that regulate
neurite outgrowth and nerve regeneration following injury have
demonstrated the involvement of ERK1/2 and p38MAPK.While
for example, it was found that the ERK and p38MAPK inhibitors,
PD98059 and SB203580, respectively, inhibited artemisinin-
induced neurite outgrowth (Sarina et al., 2013). In separate
studies of rat crushed sciatic nerves, it was also determined
that ERK activity increased on days 3 and 7 post injury while
AKT and p38 MAPK showed increasing activities from 3 to
28 days post injury (Yamazaki et al., 2009). These findings
are consistent with the idea that activation of ERK, p38
MAPK and AKT are involved in neurite outgrowth and axon
regeneration.
In this study, we provide new insight into the targeting
of both actin and tubulin by roscovitine. We demonstrate the
ability of roscovitine to interact with actin and tubulin, and
induce actin and tubulin polymerization. We also demonstrate
that in addition to enhancing actin- and tubulin-dependent
neurite outgrowth, roscovitine augments axonal regrowth and
nerve regeneration following injury. Furthermore, we show
that enhanced activation of ERK and p38 MAPK is linked to
roscovitine-induced neurite outgrowth.
MATERIALS AND METHODS
Animals and Preconditioning Lesion
Experiments
Adult male Sprague-Dawley rats (Charles River Laboratory,
Senneville, QC, Canada) with an initial weight of 300–500 g
were used and all animal studies conformed to regulatory
standards and were approved by the University of Calgary
Health Sciences Animal Care Committee. For preconditioning,
the sciatic nerve was cut at the mid-thigh region 3 days prior
to harvesting dorsal root ganglia (DRG). A sham injury in
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separate animals was performed by exposing but not severing the
sciatic nerve.
PC12 Cell Culture, R-roscovitine Treatment
and Neurite Outgrowth Analysis
PC12 cells were seeded at 1.5 × 105 and 4.5 × 105 (for western
blot analysis) into 35 mm and 60 mm tissue culture dishes,
respectively, in high serum-containing RPMI (10% horse serum,
5% fetal bovine serum) with penicillin-streptomycin. After 24 h,
cells were subjected to serum starvation in RPMI containing
0.2% horse serum and penicillin-streptomycin for 18 h. Cells
were then treated with 10 ng/ml nerve growth factor (NGF;
Invitrogen Life Technologies), and/or graded concentrations
(0.2, 2, 5, 10, 20 and 40 µM) of R-roscovitine (Invitrogen Life
Technologies) for 24 h. Neurite outgrowth was examined by
light microscopy (Olympus IX71) and images were analyzed
using the Image-Pro Express software (Media Cybernetics). The
length of neurites was analyzed using the Image-J software.
Three optical fields and 50 cells/field were evaluated for each
condition. Cell viability was assessed by trypan blue assay.
Measurements were taken from 50 cells in each treatment
(n= 3).
Western Blot Analysis
For time-course assays, cells were exposed to 10 ng/ml NGF
alone, 10 µM roscovitine alone, or both, and lysed at 0, 1, 3, 10,
30, 90 and 180 min post-treatment. Equal amounts of protein
samples were then resolved in 12.5% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and subjected to
western blot analysis using total or phospho-antibodies against
ERK1/2, p38 MAPK and AKT (Cell Signaling Technology, Inc.).
Cdk5 and HRP-conjugated secondary antibodies were from
Santa Cruz Biotechnology, Inc. and Invitrogen Life Technologies,
respectively.
Primary DRG Sensory Neuron Culture
Dissociated adult sensory neuron culture protocols using rat
DRG were as described previously (Christie et al., 2014). Briefly,
rats were anesthetized with Isoflurane (Abbot Laboratories) and
then killed 3 days following the conditioning lesion or sham
surgery. L4–L6 DRGs were removed from the rats and placed
into L15 (Invitrogen) medium. The DRGs were rinsed and
then transferred to a tube containing 2 ml 0.1% collagenase
(Invitrogen)/L15. Following incubation at 37oC, the DRGs were
placed into single-cell suspension by triturating. The single-
cell suspension was spun and washed three times in 2 ml
L15. After the final spin, the cells were resuspended in L15
and passed through a 70 mm mesh (VWR International Co.)
and then placed in 500 ml L15 enriched with 1:100 dilution
of N2 supplement (Invitrogen) and 0.1% BSA (Sigma) and
placed into a culture medium of Dulbecco’s Modified Eagle
Medium/F12 (DMEM/F12; Invitrogen) + 1:100 dilution N-2
supplement, 0.5–0.8% BSA and 0.2 ng/ml NGF (Cedarlane Labs)
plus Penicillin 50 U/ml, Streptomycin 50 U/ml (Invitrogen)
and plated on poly-L-lysine (Sigma-Aldrich) and 10 µg/ml
mouse laminin (Invitrogen)-coated cover slips. Cells were grown
for 24 h prior to roscovitine treatment (0.2, 2 or 10 µM)
for 24 h.
Immunocytochemistry of Primary DRG
Sensory Neurons
Roscovitine-treated and untreated neurons were washed with
1× Phosphate-buffered saline (PBS) and fixed with 4%
paraformaldehyde (Invitrogen Life Technologies), stained with
β-tubulin III antibody (1:200 dilution; Sigma-Aldrich Co.) in
1× PBS containing 10% goat serum and 0.3% Triton X-100 and
Cy3-conjugated anti-mouse secondary antibody (1:200 dilution;
Sigma-Aldrich Co.) in 1× PBS containing 10% goat serum
and 0.3% Triton X-100. Images were captured under a Zeiss
fluorescence microscope. Neurite length was analyzed by the
MetaXpress software and by an observer blinded to their
condition (Molecular Devices, Sunnyvale, CA, USA). Between 40
and 60 neurons were analyzed per condition. Three to four rats
per condition were routinely used. Graph Pad Prism was used
for statistical analysis. Student’s t-tests were carried out with the
statistical significance set at p ≤ 0.05.
Mass Spectrometry
R-roscovitine bound proteins were eluted from agarose beads
by SDS sample buffer and briefly subjected to SDS-PAGE.
Coomassie stained protein bands were cut and analyzed by
LC-MS/MS on a Micromass Q-ToF-2TM mass spectrometer
coupled with a Waters CapLC capillary HPLC (SAMS Centre,
University of Calgary). The peptide and protein false discovery
rates were set at 1%. A total of 22 roscovitine-interacting
proteins were identified, i.e., proteins identified and quantified
from at least two unique peptides. Keratin contaminants were
not counted. Significance values were determined by Perseus
tool using significance B. Proteins with ratio greater than 1.9
and significance B lesser than 0.1 were considered significantly
enriched. Eleven proteins listed in Figure 4B satisfied these
criteria.
R-roscovitine Agarose Pull-Down Assay
and Analysis of R-roscovitine Binding
Proteins
Lysates of PC12 cells treated with 10 ng/ml NGF or 10 ng/ml
NGF + 10 µM roscovitine for 24 h were pre-cleared with agarose
beads for 20 min and subsequently incubated with R-roscovitine
agarose beads (provided by Dr. L. Meijer, Station Biologique de
Roscoff, CNRS UPR, France) for 40 min. Beads were washed
with 50 mM Tris, pH 7.4, containing 5 mM NaF, 250 mM NaCl,
5 mM EDTA, 5 mM EGTA, 0.1% Triton X-100 and protease
inhibitor cocktail. R-roscovitine-binding proteins were eluted
from beads with 2× SDS-PAGE sample buffer and resolved
by SDS-PAGE. Separated proteins were stained with Sypro-
Ruby Red (Invitrogen Life Technologies) and detected using the
BioDoc ITTM Image System. To identify R-roscovitine-binding
proteins, pulled-down samples were subjected to SDS-PAGE and
ran into the 12.5% gel. Protein bands were cut and analyzed
by LC-MS/MS (SAMS Centre for Proteomics, University of
Calgary).
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Nerve Regeneration Analysis
Axon regrowth was analyzed in transected rat sciatic nerve as
described previously (Christie et al., 2010). An incision (3 cm)
was made on the lateral region of the left thigh from the
sciatic notch to the knee area. Another incision on the dorsal
region superior to the scapulae and parallel to the vertebrae
was performed to enable insertion of a microinjection port
(MIP). Forceps were used to create a channel through the
subdermal fascia between the incisions. Forceps were also used
to pull the MIP catheter from the anterior site to the posterior
incision. The MIP catheter was then attached to the T-chamber
access tube. The left sciatic nerve was exposed and mobilized
by blunt dissection, and transected at the mid-thigh region
with a scalpel blade (11-0). The nerve stumps were attached to
the nerve chamber with a nylon suture (Ethicon, 9-0) through
the epineurium. A 3 mm gap was left between the proximal
and distal stumps. Single sutures (Ethicon, 4-0) were used to
attach the tube’s T-intersection to the underlying muscle and
to reattach the retracted gluteal muscle. A continuous suture
(4-0) was performed to close the incisions. On days 2, 4 and
6 following nerve injury, 100 µl of 10 µM roscovitine was
administered. At the experimental end points, both the proximal
and distal nerve segments were cut a few millimeters away
from the nerve chamber. The epineurial sutures were removed
to free the nerve bridge (regenerate), which was harvested by
pulling it through the chamber. Four of the nine rats were
sacrificed to detect early regenerating fibers 7 days post-injury.
The rest (n = 5) of the animals were analyzed for regenerating
myelinated axons 21 days post-injury. Immunohistochemistry
was performed on bridges spanning the sciatic nerve transections
using mouse NF200 (1:800; Sigma) and rabbit glial fibrillary
acid protein (GFAP; 1:250; Dako) antibodies. Transected bridges
were fixed with modified Zamboni’s solution overnight at 4◦C
then rinsed in PBS and suspended in PBS-20% sucrose solution
overnight (4◦C). Samples were then frozen in optimum cutting
temperature (OCT; Tissue-Tek Sakura Finetek) and cryostat
sections (12 µM) were placed on slides that were frozen at
−80◦C. For immunostaining, tissues were permeabilized with
0.3% Triton-X in 5% goat serum and 1% BSA for 1 h. Tissues
were double labeled with NF-200 and GFAP, rinsed in PBS
and incubated with secondary CY3 sheep anti-mouse (1:100,
Sigma) and Alexa Fluor 488 goat anti-rabbit (1:500, Cedarlane)
antibodies for 1 h. Tissues were then rinsed and mounted
using Polyaquamount medium (Polysciences) and visualized
using a Zeiss Axioscope with digital camera and Axiovision
imaging software (Zeiss Axioskope, Axiovision, and Axiocam,
Zeiss, North York, ON, Canada). Profiles of serial regions (every
270 mm) perpendicular to the direction of the bridge were
examined and counted blindly.
Epon Embedding and Sectioning
Segments of nerve are fixed in 2.5% glutaraldehyde in 0.025 M
cacodylate buffer, washed with cacodylate buffer (0.15 M),
postfixed (2% osmium tetroxide in 0.12 M cacodylate buffer),
then dehydrated through graded ethanol and propylene oxide.
Next, the nerve segments undergo infiltration with a 50/50
EPON/propylene oxide mixture overnight and are thereafter
embedded in EPON and baked for 3 days (45◦C for first day and
then 65◦C for final 2 days). Central segments of the nerve bridge
(i.e., 1.5 mm from the proximal stump) are then cut into∼1 µM
sections and stained with toluidine blue.
Tubulin Polymerization Assay
Tubulin polymerization assay was performed using a kit, and
with slight modification of the manufacturer’s (Cytokeleton
Inc.) protocol. The recommendation for the in vitro tubulin
polymerization assay kit is to use tubulin at 2 mg/ml in
fluorescence buffer (80 mM PIPES pH 6.9, 2.0 mM MgCl2,
0.5 mM EGTA, 10µM fluorescent reporter) + 1 mMGuanosine-
5′-triphosphate (GTP) in black 96-well plates. As R-roscovitine
is a synthetic GTP analog, a comparable amount of R-roscovitine
was used: 0.2 mM or 0.4 mM when used alone or 0.4 mM when
used together with 0.5 mMGTP. For control, Dimethyl sulfoxide
(DMSO) and ddH2O were used instead of R-rsocovitine and
GTP, respectively. The kinetics of tubulin polymerization was
measured up to 60 min at 37◦C using a spectrophotometer
(SpectraMax M2, Molecular Devices; Softmax Pro software).
Excitation and emission wavelengths were set at 355 nm and
460 nm, respectively.
Purification of Strep-WAVE1
Strep-WAVE1 DNA construct (pAAV-CBA-ST-WAVE1) was
transfected into COS7 cells using Lipofectamine 2000 (Invitrogen
Life Technologies). After 48 h, transfected cells were lysed and
Strep-WAVE1 was purified using the Strep-Tactic Spin Column
(BioTAGnology) as described by Kim et al. (2006). Purification
of WAVE1 was assessed by SDS-PAGE and Coomassie brilliant
blue staining.
Actin Polymerization Assay
Actin Polymerization assays were performed as described by the
manufacturer (Cytokeleton Inc.). Pyrene-actin (40 µg) and non-
muscle actin (20 µg) mixed in general actin buffer (0.2 mM
ATP and 1 mM Dithiothreitol, DTT) were kept on ice for
1 h to allow depolymerization. For WAVE1 phosphorylation
by Cdk5/p25, Strep-WAVE1 (36 nM), Actin-Related Proteins
2/3 (Arp2/3) protein complex (220 nM) were incubated with
reconstituted Glutathione S-transferase (GST)-Cdk5/GST-p25
(16 µg) in 10 mM Tris-HCl buffer, pH 7.6, containing 50 µM
ATP, 5 mM MgCl2, 50 mM KCl and 5 mM EGTA, for
30 min in a 30oC. To inhibit the activity of GST-Cdk5/p25,
the strep-WAVE1 mixture was pre-incubated with 0.1 mM
R-roscovitine before adding 50 µM ATP. An equal volume of
DMSO was added to the control. For polymerization assays,
pyrene-actin and non-muscle actin mix were aliquoted into black
96-well plates along with GST-Cdk5/GST-p25-phosphorylated
WAVE1 (with or without 0.1 mM R-roscovitine) and Arp2/3
protein complex. Polymerization buffer (500 mM KCl, 20 mM
MgCl2 and 10 mM ATP) was added to initiate polymerization.
The kinetics of actin polymerization was measured up to
30 min using the SpectraMax M2 spectrophotometer at
excitation and emission wavelengths of 355 nm was 405 nm,
respectively.
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FIGURE 1 | Roscovitine enhances nerve growth factor (NGF)-mediated neurite outgrowth in PC12 cells. (A) PC12 cells were plated as described in
“Materials and Methods” Section. After 18 h in low serum DM, cells were treated with roscovitine alone (10 µM, upper right panel), NGF alone (10 ng/ml NGF; lower
left panel), or NGF and roscovitine simultaneously (lower right panel). The upper left panel shows cells that were not treated with either roscovitine or NGF.
Photographs were taken 24 h after treatment. Scale bar = 50 µM. (B) Shows the number of cells with neurites longer than 20 µM. Measurements were taken from
50 cells in each treatment (n = 3). Statistical significance using student’s t-test was set at p < 0.05∗. (C) Neurite lengths of differentiating PC12 cells were measured
24 h after treatment with NGF in the absence or presence of roscovitine at various concentrations. Untreated cells were used as control. Values are means ± SD of
three (n = 3) independent experiments. Statistical significance using student’s t-test was set at p < 0.05∗. (D) Viability of cells treated with various concentrations of
roscovitine was assessed after 24 h by cell counting using a hemocytometer. Values are means ± SD of three (n = 3) independent experiments. Statistical
significance using student’s t-test was set at p < 0.05∗.
RESULTS
Roscovitine Enhances NGF-Mediated
Neurite Outgrowth
To further investigate the role of roscovitine in neurite
outgrowth, we initially used differentiating PC12 cells. We found
that addition of roscovitine caused increased numbers of NGF-
treated differentiating PC12 cells that exhibit longer neurites
compared to those treated with NGF alone (Figures 1A,B). This
is interesting but contradicts previous reports that roscovitine
inhibits neurite outgrowth in PC12 cells (Harada et al., 2001;
Lee and Kim, 2004; Carter et al., 2008). Since we used 10 µM
roscovitine in our studies while others used 20–100 µM
(Harada et al., 2001; Lee and Kim, 2004; Carter et al., 2008),
we performed a roscovitine dose response analysis of NGF-
treated differentiating PC12 cells. As shown in Figure 1C, it
is clear that addition of roscovitine at 0.2–10 µM enhanced
neurite lengths of NGF-treated cells (p < 0.05). Roscovitine at
0.2–10 µM caused a pattern of increasing neurite lengths, with
5 and 10 µM causing significantly (p < 0.05) greater length
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of neurites compared to that caused by 0.2 µM. However, a
further increase in roscovitine concentration to 20 µM caused
a drastic decrease (p < 0.05) in neurite length compared to
treatment with 5 and 10µM.Neurite length at 20µMroscovitine
is comparable to that of cells treated with NGF alone. While
roscovitine has been shown to cause apoptosis (Gao et al., 2005;
Zheng et al., 2007), we found that concentrations at which it
can enhance neurite length (up to 10 µM) were insufficient
to cause significant cell death (Figure 1D) but increasing the
concentration to 20 and 40 µM caused loss of cell viability
by ∼60% and almost 100%, respectively (p < 0.05). Thus,
our findings demonstrate that at lower concentrations, i.e.,
at 0.2–10 µM, roscovitine enhances neurite length instead of
neuronal apoptosis.
Roscovitine Enhances Axonal Regrowth
Repair of peripheral nerve injury normally requires axonal
regrowth (Christie et al., 2014). Therefore, we examined the
possibility that roscovitine can enhance axon regrowth in ex vivo
adult primary neurons. For this experiment, adult male Sprague-
Dawley rats were subjected to sciatic nerve transection at the
mid-thigh region. After 3 days, L4 to L6 DRG were isolated
from these rats, dissociated, and cultured to examine whether
roscovitine will affect neurite outgrowth of these pre-injured
primary sensory neurons. As with differentiating PC12 cells,
we noted increased number and significantly (p < 0.05) longer
neurites in cells treated with 0.2 µM roscovitine (Figures 2A,B).
At this concentration, the average length of neurites was
about twice those of neurons not treated with roscovitine.
Interestingly, unlike in PC12 cells, increasing the concentration
of roscovitine to 2 and 10 µM did not cause a pattern of
increasing neurite length. DRG neuronal cell viability, upon
addition of 2 and 10 µM roscovitine, trended toward a decline
(data not shown). Although PC12 cells and primary neurons
exhibit different sensitivities to roscovitine at 0.2–10 µM, it is
clear that roscovitine can cause increased neurite length/axon
regrowth in differentiating PC12 cells and preconditioned/pre-
injured neurons.
Roscovitine Increases the Number of
Myelinated Axons that Repopulate
Regenerating Rat Sciatic Nerve
Given our in vitro and ex vivo findings, we wondered whether
roscovitine would improve axon regrowth in an adult rat
in vivo regenerative model following total peripheral nerve trunk
transection. A 3–5 mm gap was created after sciatic nerve
transection and subsequent nerve retraction of the proximal
and distal stumps; a scenario that simulates human nerve
injury (Figure 3A). Administration of roscovitine was performed
using a silicone conduit as described previously (McDonald
and Zochodne, 2003). Repeated injections of 100 µl of 10 µM
roscovitine or Ringer’s solution were performed on days 2, 4 and
6 (n = 9). Four of the nine rats were sacrificed for detection of
early regenerating fibers on day 7 post-injury. The rest (n= 5) of
the animals were analyzed for regenerating myelinated axons on
day 21 post-injury. Since myelinated axons have not yet appeared
FIGURE 2 | Roscovitine enhances axonal regrowth of pre-injured rat
primary dorsal root ganglia (DRG) sensory neurons. (A) Neurons isolated
from rat L4–L6 DRGs 3 days after sciatic nerve transection were cultured on
laminin and poly-L-lysine coated cover slips in primary neuron media,
containing N-2 supplement, BSA and 0.2 ng/ml NGF, in the absence or
presence of roscovitine (0.2, 2.0 or 10 µM). After 48 h, cells were fixed in 4%
paraformaldehyde and immunostained with β-III tubulin antibody. Scale
bar = 50 µM. (B) Axon lengths of DRG neurons exposed to different
concentrations of roscovitine. Values are means ± SD of three independent
experiments. Statistical significance using student’s t-test was set at
p < 0.05∗.
on day 7 post-injury, we performed immunohistochemistry of
longitudinal sections at this time point to obtain an index of
early outgrowth when the earliest fibers begin to enter the
regenerative stump. However, we found that roscovitine had no
significant effect on early axon outgrowth in transected sciatic
nerve 7 days after treatment (Figures 3B,C). On day 21 post-
injury, immunohistochemistry imaging fields are crowded by
a host of new fibers making discrete counting problematic.
Thus, for day 21 post-injury samples, we analyzed EPON
embedded semi-thin sections to appraise early and successful
reconstitution of myelinated axons. Indeed, at 21 days following
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FIGURE 3 | Roscovitine increases the number of myelinated axons in regenerating rat sciatic nerve. Adult male SD rats were subjected to sciatic nerve
transection as described in “Materials and Methods” Section. (A) A schematic diagram showing the sciatic nerve lesion, the regeneration chamber and cutting site of
EPON embedded section that lies perpendicular to the direction of the bridge. (B) Analysis of the number of axons with Schwann cells (SC) in control and
roscovitine-treated rats 7 days after sciatic nerve transection. Axonal outgrowth were measured by serial counts (fields 1–7) proximal to the distal stump of a cut
sciatic nerve by co-immunohistochemical staining for neurofilament (for neurons) and glial fibrillary acid protein (GFAP; for SC). Values are means ± SD; n = 4.
Changes in values did not reach to statistical significance using Student’s t-test at p ≤ 0.05. (C) Representative image of axons with SC (examined in B) in control
and roscovitine-treated rats at 7 days. Arrowheads are directed at axons. (D) Twenty-one days post-transection, axonal regeneration was evaluated by morphometric
analysis of toluidine blue-stained EPON embedded cross sections of sciatic nerve bridges treated with Ringer’s solution (left panel) or 10 µM roscovitine (right panel).
Arrow is directed at a myelinated axon. (E) Analysis of the number of myelinated axons (left panel) and axon caliber (right panel) in control (Ringer’s solution-treated)
and roscovitine-treated rats 21 days after sciatic nerve transection. Values are means ± SD; n = 5. Statistical significance using student’s t-test was set at p < 0.05∗.
sciatic nerve transection, morphometric analysis of sections from
the central portions of the nerve bridges revealed significantly
(p < 0.05) increased numbers of repopulating myelinated axons
in the roscovitine-treated group compared to the control group
(Figures 3D,E left panel). We also assessed axon caliber but
found no significant difference between the roscovitine-treated
nerves and the control group. Overall, these observations extend
our in vitro and ex vivo findings, indicating that roscovitine can
be translated into a significant in vivo paradigm, with an impact
on myelinated fiber repopulation of regenerating nerves.
Roscovitine Interacts with Tubulin and
Actin in Differentiating PC12 Cells
To understand the underlying molecular mechanism(s) behind
roscovitine-induced increase in neurite outgrowth, axonal
regrowth and peripheral nerve regeneration, we sought to
identify the neuronal targets of roscovitine. To do so, lysates
of differentiating PC12 cells treated with NGF and roscovitine
were used for R-roscovitine-agarose pull-down assays. As shown
in Figure 4A, after pre-clearing the cell lysates with agarose
beads and mass spectrometry of the pulled down sample,
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FIGURE 4 | Identification of roscovitine interacting proteins in
differentiating PC12 cells. (A) Neuronal differentiation of PC12 cells was
induced using NGF. After pre-clearing with agarose beads, differentiating
PC12 cell lysates were subjected to pull-down assay using
roscovitine-agarose beads. The pulled-down proteins were analyzed by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and
stained with Sypro-Ruby Red (upper panel). A parallel SDSPAGE loaded with
the same samples and analyzed by western blotting showed immunoreactivity
to extracellular signal-regulated kinases 1/2 (ERK1/2) and Cdk5. (B)
Pulled-down proteins were also analyzed by mass spectrometry. A list of
roscovitine interacting proteins in differentiating PC12 cells treated with NGF
and roscovitine is shown.
we determined that the R-roscovitine-agarose beads effectively
bound the known roscovitine targets, Cdk5 and ERK1/2 (Bach
et al., 2005). We also detected binding of nine other known
roscovitine targets, including calmodulin (CaM)-dependent
kinases, casein kinase 1 (CK1) and pyridoxal kinase (PDXK;
Bach et al., 2005; Figure 4B). However, we also detected two
additional roscovitine-interacting proteins, tubulin and actin.
Since peripheral nerve regeneration is dependent upon rapid
polymerization of microtubules and dynamics of actin filaments
in the growth cone (Kalil and Dent, 2005), we proceeded to
characterize the interaction of roscovitine with tubulin and actin.
Roscovitine Enhances Tubulin
Polymerization
To characterize the interaction between tubulin and roscovitine,
we initially performed R-roscovitine-agarose bead pull down
assay of purified tubulin and mouse brain homogenates pre-
incubated/-cleared with agarose beads. By western blotting
(Figure 5A), we found that mouse brain homogenate tubulin
(lane 1) and purified tubulin (lane 4) bound to the roscovitine
beads while preincubation of purified tubulin with roscovitine
prevents their interaction (lane 3), indicating that tubulin directly
binds to roscovitine. We then examined whether roscovitine
affects tubulin polymerization. To assess this possibility, we
examined polymerization of tubulin in the presence and absence
of roscovitine. As shown in Figure 5B, roscovitine by itself
caused a dose-dependent increase in tubulin polymerization (◦).
Following normalization (subtraction of values at time 0), we
detected more than 2-fold increase in tubulin polymerization
upon addition of roscovitine alone. When added together with
GTP, roscovitine caused earlier nucleation and enhanced rate
FIGURE 5 | Roscovitine interacts with tubulin directly, and enhances
tubulin polymerization. (A) Mouse brain homogenate (lane 1) and purified
tubulin (lanes 3 and 4) were pre-cleared/-incubated with agarose beads and
subsequently incubated with roscovitine-agarose beads. Tubulin binding to
roscovitine beads was analyzed by western blotting using a tubulin antibody.
Purified tubulin served as positive control (lane 2). For negative control (lane 3),
tubulin was pre-incubated with 0.2 mM roscovitine (ros) prior to incubation
with roscovitine-agarose beads. Note that no agarose-tubulin binding was
observed after a second pre-clearing of brain homogenates.
(B) Spectrophotometric tubulin polymerization assay was performed using a
kit, and with slight modification of the manufacturer’s (Cytokeleton Inc.)
protocol. To obtain detectable levels of polymerization, the recommendation
for the in vitro tubulin polymerization assay kit is to use tubulin at 2 mg/ml in
fluorescence buffer (80 mM PIPES pH 6.9, 2.0 mM MgCl2, 0.5 mM EGTA,
10 µM fluorescent reporter) + 1 mM Guanosine-5′-triphosphate (GTP). As
R-roscovitine is a synthetic GTP analog, a comparable amount of
R-roscovitine was used: 0.2 mM or 0.4 mM when used alone or 0.4 mM when
used together with 0.5 mM GTP. Analysis of: polymerization of
4′,6-diamidino-2-phenylindole (DAPI)-tubulin alone () or (1) incubated with
increasing concentrations of roscovitine (◦; 0.2 mM or 0.4 mM); or (2) GTP
(•, positive control; 0.5 mM), or GTP and roscovitine (∆; 0.5 mM and 0.4 mM,
respectively). Data from the two independent analyses with similar range of
fluorescence values are shown together.
(∆) of GTP-dependent (•) tubulin polymerization. Indeed,
the time needed to complete GTP-dependent polymerization
was cut in half upon addition of roscovitine (15 min vs.
30 min).
Roscovitine Enhances
Arp2/3/Wave1-Mediated Actin
Polymerization
Next, we examined actin interaction with roscovitine with
a further pull-down assay and western blot analysis. As
shown in Figure 6A, although actin in pre-cleared mouse
brain homogenates (lane 1) bound to the roscovitine
beads, purified actin (lane 4) did not, indicating that actin
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FIGURE 6 | Roscovitine interacts with actin indirectly, and enhances Actin-Related Proteins 2/3 (Arp2/3)/Wave1-mediated actin polymerization.
(A) Mouse brain homogenate (lane 1) and purified actin (lanes 3 and 4) were pre-cleared/-incubated with agarose beads and subsequently incubated with
roscovitine-agarose beads. Actin binding to roscovitine beads was analyzed by western blotting using an actin antibody. Purified actin served as positive control (lane
2). For negative control (lane 3), actin was pre-incubated with 0.2 mM roscovitine (ros) prior to incubation with roscovitine-agarose beads. The lack of actin
immunoreactivity in lane 4 indicates that actin in the brain homogenate (lane 1) interacts with roscovitine indirectly. Note that no agarose-actin binding was observed
after a second pre-clearing of brain homogenates. (B) SDS-PAGE and Coomassie brilliant blue staining of purified Glutathione S-transferase-cyclin-dependent
kinases 5 (GST-Cdk5; left panel), GST-p25 (middle panel; Cdk5 activator) and Strep-Wave1 complex (right panel). Asterisks correspond to the heat shock chaperon
protein that copurifies with GST-Cdk5 and GST-p25. (C) Polymerization curve of pyrene-actin incubated with Arp2/3 ±Wave1 complex ± Cdk5/p25 ± preincubation
with roscovitine. Values shown are obtained following a preincubation time of 11 min and fluorescence was set to an arbitrary value of zero. For all treatments,
fluorescence start to plateau at ∼27 min. (D) Western blot for Wave1 phospho-Ser310 showing that Cdk5/p25 phosphorylates Wave1 at Ser310 and this
phosphorylation is inhibited by roscovitine. (E) Densitometric analysis of the representative blot in (D) using the NIH Image-J 1.61 software.
(in brain homogenates) binds to roscovitine indirectly.
Indeed, actin is known to bind to Cdk5 (Xu et al., 2011), a
recognized direct target of roscovitine. Since Cdk5 has been
shown to inhibit Arp2/3-dependent actin polymerization
through phosphorylation of Wave1 (Kim et al., 2006), we
examined whether roscovitine, a known Cdk5 inhibitor,
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could rescue actin polymerization. For this experiment,
we used recombinant Cdk5 (Figure 6B, left panel), p25
(Cdk5 activator; Figure 6B, middle panel) and Wave1
(Figure 6B, right panel) that, as described previously (Kim
et al., 2006), forms a complex and copurifies with endogenous
PIR121, Nap1 and Abi2. We found that roscovitine, indeed,
completely reversed the Cdk5/p25 inhibition of Arp2/3-Wave1-
mediated actin polymerization (Figure 6C). Since under our
experimental conditions, Cdk5/p25 clearly phosphorylates
Wave1 (Figures 6D,E, lane 4 and bar 4, respectively),
and roscovitine noticeably inhibits such phosphorylation
(Figures 6D,E, lane 5 and bar 5, respectively), our results
indicate that roscovitine-induced actin polymerization occurred
through roscovitine interaction with Cdk5, which prevented
Cdk5-mediated phosphorylation of Wave1 and subsequently,
prevented Cdk5 inhibition of Arp2/3-Wave1-mediated actin
polymerization.
Roscovitine Causes Enhanced Activation
of ERK1/2 and p38 MAPK in NGF-Treated
Differentiating PC12 Cells
ERK1/2, p38 MAPK and AKT have been implicated in neurite
outgrowth and axonal regeneration (Agthong et al., 2009;
Okada et al., 2011; Wang et al., 2011; Kato et al., 2013;
Sarina et al., 2013; Mufti et al., 2014). Therefore, we wondered
whether increased axon regrowth resulting from roscovitine
treatment is due to synergistic activation of ERK1/2, p38 MAPK
and/or AKT signaling pathways in addition to enhancement
of tubulin and actin polymerization. For this experiment, we
again used PC12 cells as a substantial number of injured rats
would be required to obtain a sufficient number of DRG
neurons for several western blots. Lysates of differentiating
PC12 cells grown in the presence of NGF with or without
roscovitine were examined for the phosphorylation levels of
ERK1/2, p38 MAPK and AKT. As shown in Figures 7A,B,
simultaneous treatment with NGF and roscovitine (middle
panels) caused considerable activation of ERK1/2 and p38
MAPK at an earlier time point (1 min) compared to cells
treated with NGF alone (3 min; left panels). In addition, we
observed enhanced and prolonged activation of ERK1/2 in
cells treated with NGF + roscovitine (90 min) compared to
cells treated with roscovitine alone (30 min). While we also
noted AKT activation following treatment with NGF, addition
of roscovitine did not cause a change in activation of this
kinase.
DISCUSSION
It is recognized that triggering the cell cycle plays a role
in post-mitotic cell death. Interestingly, activation of the
cell cycle has also been implicated in secondary damage
following injury to the spinal cord (Byrnes et al., 2007).
Consequently, blocking major cell cycle signaling molecules
inhibits not only cell proliferation but also injury-related cell
death. For example, in rodent spinal cord injury models, it
was shown that inhibiting the cell cycle results in a reduction
of both neuronal death and inflammation, and subsequently,
improved sensory motor recovery (Wu et al., 2011). The
synthetic purine analog, roscovitine, has been shown to regulate
both the cell cycle and inflammatory process but a potential
role in sensory motor neuron recovery has not yet been
investigated.
Our current findings suggest that roscovitine, which inhibits
cell cycle Cdks, has the ability to promote nerve regeneration.
In this study, myelinated axons were chosen as an index of
maturating fibers and to establish a correlation with functional
outcome. While early measurements in a nerve conduit and
in vitro are unmyelinated as we assessed by day 7, some are
destined to grow in caliber and become myelinated. Thus, this
population of fibers (early unmyelinated) does not necessarily
predict later myelinated axon repopulation of a mature nerve.
Unmyelinated counts can also be complex later since they
are a mix of fibers destined to remain unmyelinated and
axons that will be myelinated later. By focusing on myelinated
axons, we believe we have a better index of the population
that translates into functional recovery. As shown in our
adult rat in vivo regenerative model system, treatment with
low-dose roscovitine following total peripheral nerve trunk
transection caused an increase in number of repopulating
myelinated axons. Although we could not disregard the fact
that roscovitine binds to several ATP-dependent protein targets,
and principally, GTP- or NAD-dependent protein kinases
(Bach et al., 2005), its ability to interact with tubulin and
actin, may be a major mechanism in its ability to promote
axonal regeneration. It is possible that inosine effect on
collateral axon growth (Dachir et al., 2014) and adenosine
and/or guanosine effects on axonal degeneration and axon
preservation after injury (Press and Milbrandt, 2009) occur
through a similar mechanism.
Indeed, we found that roscovitine binds to tubulin directly
and such interaction causes tubulin polymerization that is
independent of GTP. In the presence of GTP, roscovitine has
the ability to induce earlier nucleation and enhance the rate of
tubulin polymerization. This may be explained by roscovitine
binding to the tubulin exchangeable nucleotide-binding site (E-
site) with high affinity (De Azevedo et al., 1997; Gray et al.,
1999). Consistent with this suggestion, it has been shown that an
analog of GTP, guanylyl-(alpha, beta)-methylene-diphosphonate
(GMPCPP), which is insensitive to hydrolyzation, favors
polymerization by strongly promoting spontaneous nucleation of
microtubules (Hyman et al., 1992) which is critical for the early
stages of microtubule assembly (Wang et al., 2005).
On the other hand, roscovitine does not bind actin directly.
Therefore, its ability to enhance actin polymerization is likely
due to its interaction with other intermediate proteins. Indeed,
Cdk5, a direct target of roscovitine (Bach et al., 2005), has
the ability to bind actin (Xu et al., 2011). Previously, Kim
et al. (2006) reported that WAVE1 phosphorylation by Cdk5
directly interferes with Arp2/3-dependent actin polymerization,
which is known to be critical for growth cone formation.
Since roscovitine is a potent inhibitor of Cdk5, roscovitine
binding and inhibition of Cdk5 activity could account for
the enhanced polymerization effect on actin by roscovitine.
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FIGURE 7 | Roscovitine enhances the activation of ERK1/2 and p38 mitogen-activated protein kinase (MAPK) in differentiating NGF-treated PC12
cells. (A) Representative set of blots (from three sets/independent experiments) of lysates of PC12 cells plated and treated as described in “Materials and Methods”
Section. After serum starvation for 18 h, cells were treated with NGF alone (10 ng/ml; left panel), roscovitine alone (10 µM; right panel) or NGF+roscovitine
simultaneously (middle panel), and lysed at 0, 1, 3, 10, 30, 90 and 180 min post-treatment. Equal amounts of protein samples were then resolved in 12.5%
SDS-PAGE and subjected to
(Continued)
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FIGURE 7 | Continued
western blot analysis using phospho-antibodies against ERK1/2, p38 MAPK
and AKT. Additional test for loading equivalent amounts of protein was
performed by Ponceau S staining. (B) The ratios of the band intensities [from
the representative blots in (A)] of phospho-ERK1/2, phospho-p38 MAPK and
phospho-Akt vs. total ERK, total p38 MAPK and total Akt, respectively, were
determined following densitometric scanning of bands using the NIH Image-J
1.61 software. Note the different Y-axis scales for p-ERK1/total ERK (left) and
p-ERK2/total ERK (right). Analysis of the ratios of the band intensities of
phospho-AKT vs. total AKT did not show any considerable changes at
different time points in the three treatment groups. (C) Proposed molecular
mechanisms by which roscovitine enhances NGF-induced axonal regrowth.
Roscovitine promotes axonal regrowth by inducing tubulin and actin
polymerization (left panel). In the presence of NGF, roscovitine enhances
axonal regrowth through activation of the ERK1/2 and p38 MAPK pathways.
Incidentally, this further supports the notion that Cdk5 serves
as an inhibitor of actin polymerization (Kim et al., 2006).
Thus, our findings suggest that roscovitine promotes not
only tubulin-dependent neuronal functions but also actin-
dependent functions. These roscovitine roles may, indeed,
occur during roscovitine-induced neurite outgrowth, ex vivo
axon regrowth and regeneration of injured sciatic nerve
in rats.
It is interesting that, although PC12 cells exhibit a dose-
dependent increase in neurite outgrowth from 0.2 to 5 µM
roscovitine, primary DRG sensory neurons isolated following
sciatic nerve transection showed amore enhanced axon regrowth
at a lower roscovitine concentration. In other words, axonal
regeneration in pre-injured primary DRG sensory neurons
is greater at 0.2 µM than at 2 µM roscovitine, and 2 µM
elicited greater axon regrowth than 10 µM. This appears
to suggest that primary DRG sensory neurons have greater
uptake ability for roscovitine compared to differentiating PC12
cells, or that the primary DRG sensory neurons have better
representation of neural properties. It is also possible that
increased sensitivity of DRG neurons to roscovitine is due to
the difference in the required culture conditions to induce
neurite outgrowth. While PC12 cells were cultured in the
presence of 10 ng/ml NGF to induce differentiation, DRG
primary neurons are maintained in media containing 0.2 ng/ml
NGF. Thus, it appears that with the higher amount of NGF in
PC12 cell cultures, which can already cause neurite outgrowth,
a higher concentration of roscovitine is needed to see an
enhanced effect on neurite outgrowth. Conversely, a relatively
lower concentration of roscovitine is needed in DRG neuronal
cultures, which are grown in low NGF media, to see an
axon regrowth promoting effect. Nonetheless, our findings
indicate that roscovitine has a parallel impact on neurite/axon
regrowth in PC12 cells and in preconditioned/pre-injured
neurons.
ERK1/2, p38 MAPK and AKT have all been implicated in
neurite outgrowth and axonal regeneration (Agthong et al., 2009;
Okada et al., 2011; Wang et al., 2011; Kato et al., 2013; Sarina
et al., 2013). In this study, we also found that these kinases
are activated in differentiating PC12 cells. However, we further
found that roscovitine causes earlier activation of ERK1/2 and
p38MAPK as well as prolonged activation of ERK1/2. This is not
surprising as roscovitine’s IC50 values for ERK1, ERK2 and p38
MAPK are quite high as indicated above. Thus, while roscovitine
may inhibit MAPKs at high concentrations (i.e., greater than
their respective IC50 values) the low-dose roscovitine that we
used (10 µM) has no inhibitory effect but instead, enhanced
the activation of ERK1/2 and p38 MAPK. These findings
suggest that both ERK1/2 and p38 MAPK are involved in
roscovitine-induced neurite outgrowth and axonal regeneration.
Indeed, there has been an earlier report that activation of
ERK1/2 and p38 MAPK is linked to neurite outgrowth in
PC12 cells (Sarina et al., 2013). Thus, consistent with our
findings, we propose a model (Figure 7C) whereby roscovitine
promotes axonal regrowth through induction of tubulin and
actin polymerization. In the presence of neurotrophic factors,
such as NGF, axonal regrowth is enhanced by roscovitine via
increased activation of the p38 MAPK and ERK1/2 signaling
pathways.
Interestingly, the ERK1/2 pathway has been associated
with the promotion of dedifferentiation of myelinating SC
(Jessen and Mirsky, 2008; Napoli et al., 2012), a process
that supports axon regeneration. In addition, p38 MAPK
activation induces denervated SC phenotype and negatively
regulates SC differentiation and myelination (Yang et al.,
2012). However, once axons have started to regenerate, SC
redifferentiate and remyelinate. Thus, our finding that enhanced
activation of ERK1/2 and p38 MAPK play important roles in
neurite outgrowth in neuronal cultures complements previous
suggestions that these kinases are key regulators of axonal
regeneration.
Certainly, roscovitine-induced actin and tubulin
polymerization may explain our in vitro, ex vivo and in
vivo data, demonstrating enhancement of neurite outgrowth
in neuronal-like PC12 cells, axonal regrowth in primary
DRG sensory neurons and induction of regeneration of
transected rat sciatic nerve, respectively. While it should
be noted that depolymerization is at least as important
as polymerization in mobilizing microtubular plasticity in
the growth cone, our premise that the ability of roscovitine
to enhance tubulin polymerization is linked to its ability to
induce regeneration of injured rat sciatic nerve is consistent
with recent reports. Indeed, the anti-cancer agents, paclitaxel
(Hellal et al., 2011) and epothilone B (Ruschel et al., 2015),
both of which stabilize microtubules, promote axon regrowth.
Furthermore, the ability of epothilone B to induce axon
regrowth was shown to cause restoration of locomotive
function in a rat spinal cord injury model (Ruschel et al.,
2015). Interestingly, roscovitine is currently under phase II
clinical trial in combination with standard chemotherapy
regimens for advanced breast cancer and stage IIIB/IV
non-small cell lung cancer (Aldoss et al., 2009; Nair et al.,
2011). It appears that the microtubule-mediated mechanisms
of roscovitine- and epothilone B-induced nerve repair are
similar.
Taken together, our findings point to a therapeutic potential
of roscovitine for peripheral nerve injury. Therefore, the next
step is to assess this potential by initial functional recovery tests
in animals and, if promising, subsequently in human clinical
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testing. If, indeed, promising, much remains to be explored
on the potential use of roscovitine as therapy for peripheral
nerve injury, aside from appropriate route of administration,
toxicity profile and maximum tolerated dose. Given its role in
axon protection and regrowth, and potential for cancer therapy,
roscovitine may simultaneously offer some protection against
chemotherapy-induced neuropathy, a possibility that is worth
exploring.
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